Chronic Hepatitis C and HCC : What is new?

Volanesorsen reduced mean apolipoprotein C-III levels from baseline by 84% after 3 months of therapy and by 83% after 6 months of therapy (P<0.001 for both comparisons),

Vel fi gravara effet mealier , qux cum viro con- traxiflèt extra territorium; quæ etiam(i non re- rdeat in loco (ibi aíiignato, non debet privari't majoratu ex eo quód

Materials and Methods: The present work presents six (6) cases of patients with massive bone loss treated by means of what we call a “synergistic combination” of an

Introduction: The aim of this study is to evaluate results in a series of patients with chronic posterior-lateral instability of the elbow treated with reconstruction of the

Core tip: The Milan criteria for liver transplantation have improved survival of patients with small hepatocellular carcinoma (HCC), but up to 20% of patients still experience

Antiviral activity of Polyanionic Carbosilane Dendrimers as hepatitis C virus entry inhibitors. (Manuscript

We have evaluated the performance of a deep-sequencing-based HCV subtyping assay, developed for the 454/GS-Junior platform, in comparison with those of two commercial assays

In conclusion, the results of this study analyzing treatment outcomes for LDV/SOF against HCV genotype 1 in treatment- naïve noncirrhotic patients suggest that HIV infection is a